These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 801618)

  • 1. [Clinical trial with a combination of 150 mcg of d-norgestrel and 30 mcg of ethinylestradiol. Its metabolic effects].
    Moggia AV; Koremblit E; Beauquis A
    Obstet Ginecol Lat Am; 1976; 34(11-12):384-97. PubMed ID: 801618
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolic effects of a combination of dl-norgestrel and ethinylestradiol in humans.
    Gerhards E; Lachnit U; Gaude R; Schillinger E
    Arzneimittelforschung; 1973 Jun; 23(6):779-84. PubMed ID: 4740760
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical study of a new mini-dosed estro-progestative combination (30 mcg of ethinyl estradiol and 150 mcg of D-norgestrel)].
    Muller P; Dellenbach P
    Sem Hop Ther; 1975 Feb; 51(2):91-4. PubMed ID: 1162385
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical evaluation of an oral contraceptive combination with a low dosage of estrogens and progestanes and their correlation in a group of women using intrauterine device].
    Rinaldi A
    Rev Chil Obstet Ginecol; 1977; 42(1):34-40. PubMed ID: 351745
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical study and effect on the uterine receptor of the combination Norgestrel-Ethinyl-Estradiol (FH 122-A) in 500 menstrual cycles].
    Lévrier M
    Bord Med; 1970 Jan; 3(1):225-6. PubMed ID: 4948561
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative studies of two oral contraceptives containing DL norgestrel and D norgestrel.
    Koetsawang S; Rimdusit S; Srivanaboon S; Bhiraleus P; Rachawat D
    J Med Assoc Thai; 1973 May; 56(5):314-8. PubMed ID: 4783789
    [No Abstract]   [Full Text] [Related]  

  • 7. [The efficacy of gestoden (delta 15-d-norgestrel) as ovulation inhibitor (author's transl)].
    Schneider WH; Schmid R; Spona J
    Wien Klin Wochenschr; 1981 Oct; 93(19):601-4. PubMed ID: 6798765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical trials of an association of norgestrel and ethinyl estradiol commercialized under the name of Stediril].
    Gaudefroy M; Corette L; Coliche D
    Bull Fed Soc Gynecol Obstet Lang Fr; 1971; 23(4):434. PubMed ID: 5153231
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparison in changes in blood coagulation tests during use of oral contraceptives. First symposium - sexual steroids].
    Castillo JD; Mendoza C
    Rev Colomb Obstet Ginecol; 1975; 26(1):53-7. PubMed ID: 1144891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of norgestrel in combination with ethinyl oestradiol on the human pituitary-adrenal axis.
    Givens JR; Fort AT; Leigh JH
    J Reprod Fertil Suppl; 1968 Dec; 5():Suppl 5:69-76. PubMed ID: 4330931
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral contraception, 1986. Focus on Triphasil.
    Ellsworth H
    J Reprod Med; 1986 Jun; 31(6 Suppl):559-64. PubMed ID: 3522896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Action of hormonal contraceptives on the coagulation system and some of its inhibitors.
    Misz M; Beck P
    Acta Med Hung; 1986; 43(3):301-10. PubMed ID: 2438639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of menstruation and Microgynon 30 on sway behaviour.
    Graham SE; Thornton H; Atha J
    Agressologie; 1978; 19(B):55-6. PubMed ID: 727358
    [No Abstract]   [Full Text] [Related]  

  • 14. Progestagens, blood-clotting, and blood-pressure.
    Lancet; 1977 Nov; 2(8047):1085-6. PubMed ID: 72996
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of a synthetic estrogen-progestogen agent on urinary gonadotropin levels of FSA and LH using a radioimmunologic method.
    Forleo R; Vegna G; Pala A
    Acta Eur Fertil; 1972 Jun; 3(2):159-76. PubMed ID: 4679575
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind comparison of two oral contraceptives containing 50 mu g. and 30 mu g. ethinyl estradiol.
    Dionne P; Vickerson F
    Curr Ther Res Clin Exp; 1974 Apr; 16(4):281-8. PubMed ID: 4208342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral contraceptives and blood coagulation.
    Bonnar J; Sabra AM
    J Reprod Med; 1986 Jun; 31(6 Suppl):551-6. PubMed ID: 2941571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relevance of the pharmacologic properties of a progestational agent to its clinical effects as a combination oral contraceptive.
    Upton GV; Corbin A
    Yale J Biol Med; 1989; 62(5):445-57. PubMed ID: 2534253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.